Get the Stockscreener App
4.20
2.69%
0.11
Recursion Pharmaceuticals Inc stock is traded at $4.20, with a volume of 16.02M.
It is up +2.69% in the last 24 hours and down -2.78% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
See More
Previous Close:
$4.09
Open:
$4.17
24h Volume:
16.02M
Relative Volume:
0.40
Market Cap:
$2.19B
Revenue:
$64.60M
Net Income/Loss:
$-377.75M
P/E Ratio:
-2.7097
EPS:
-1.55
Net Cash Flow:
$-335.64M
1W Performance:
-1.18%
1M Performance:
-2.78%
6M Performance:
-19.39%
1Y Performance:
-41.75%
1-Day Range:
$4.12
$4.23
1-Week Range:
$4.05
$4.31
52-Week Range:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.20 | 2.13B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Recursion Pharmaceuticals Stock (RXRX) Opinions on Analyst Upgrade and Insider Trading - Quiver Quantitative
Here’s What J.P. Morgan Thinks About Recursion Pharmaceuticals (RXRX) - Insider Monkey
JPMorgan boosts rating on Recursion Pharmaceuticals (RXRX) amid AI-driven drug pipeline - MSN
JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline - Insider Monkey
Bank Pictet & Cie Europe AG Acquires Shares of 1,630,000 Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals reports positive Phase 1b/2 TUPELO trial results, validating AI-driven therapy for FAP - MSN
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. - Finviz
Cathie Wood’s ARK Investment buys 755K shares of Recursion Pharmaceuticals, Inc. (RXRX) - MSN
Cathie Wood’s ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) - Insider Monkey
Cathie Wood's ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) - Finviz
Recursion Pharmaceuticals (NASDAQ:RXRX) CFO Ben Taylor Sells 21,383 Shares - MarketBeat
Taylor, CFO of Recursion Pharmaceuticals, sells $89k in shares By Investing.com - Investing.com UK
Taylor, CFO of Recursion Pharmaceuticals, sells $89k in shares - Investing.com
RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025) - ts2.tech
Best Biotech Stocks To Follow NowDecember 26th - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Najat Khan Sells 124,403 Shares - MarketBeat
RXRX Stock Plummet: Here’s What’s Happening - timothysykes.com
Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP - Insider Monkey
10 AI Stocks Under $20 to Buy Now - Insider Monkey
Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform - Finviz
Cathie Wood is doubling down on Recursion Pharmaceuticals stock. Should you buy RXRX here? - MSN
Recursion Pharmaceuticals Stock (RXRX) Opinions on Analyst Upgrade and Clinical Data - Quiver Quantitative
Growth or Bubble? Decoding Recursion Pharmaceuticals’ Stock Surge - timothysykes.com
3 Small AI Plays to Buy for 2026 - Sahm
Is Recursion Pharmaceuticals, Inc. (RXRX) the best fundamentally strong penny stock to buy? - MSN
Is Recursion (RXRX) Finally Proving Its AI Drug Discovery Model With REC-4881’s Early Data? - simplywall.st
Recursion Pharmaceuticals (RXRX) Stock News Today: Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition - ts2.tech
Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? - Barchart.com
Top Biotech Stocks To ResearchDecember 17th - MarketBeat
How Investors May Respond To Recursion Pharmaceuticals (RXRX) Early FAP Trial Success And AI Platform Validation - Yahoo Finance
Is Recursion Pharmaceuticals Inc. stock overvalued by current metricsJuly 2025 Market Mood & High Accuracy Trade Alerts - Bölüm Sonu Canavarı
Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock - AOL.com
Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades - Yahoo Finance
Aug Retail: Will Recursion Pharmaceuticals Inc stock gain from lower inflationMarket Volume Summary & Daily Profit Maximizing Trade Tips - moha.gov.vn
Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? - Insider Monkey
Recursion Pharmaceuticals RXRX Stock News and Forecasts on December 21 2025 - ts2.tech
Recursion Pharmaceuticals (RXRX) Price Target Increased by 10.53% to 7.14 - Nasdaq
Is Recursion Pharmaceuticals Inc. stock a safe buy before earningsJuly 2025 Macro Moves & Free Real-Time Volume Trigger Notifications - Улправда
Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next - ts2.tech
Published on: 2025-12-19 22:42:25 - Улправда
CEO Gibson Files To Sell 40,000 Of Recursion Pharmaceuticals Inc [RXRX] - TradingView — Track All Markets
Will Recursion Pharmaceuticals Inc. stock benefit from green energy trends2025 Trading Recap & AI Based Trade Execution Alerts - DonanımHaber
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Recursion Pharmaceuticals Inc Stock (RXRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Khan Najat | Chief R&D Commercial Officer |
Dec 22 '25 |
Sale |
4.41 |
124,403 |
548,592 |
611,135 |
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):